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Abstract
Although the inﬂuenza A (H1N1) 2009 virus is expected to circulate as a seasonal virus for some years after the pandemic period, its
behaviour cannot be predicted. We analysed a prospective cohort study of hospitalized adults with inﬂuenza A (H1N1) 2009 pneumonia
at 14 teaching hospitals in Spain to compare the epidemiology, clinical features and outcomes of inﬂuenza A (H1N1) 2009 pneumonia
between the pandemic period and the ﬁrst post-pandemic inﬂuenza season. A total of 348 patients were included: 234 during the pan-
demic period and 114 during the ﬁrst post-pandemic inﬂuenza season. Patients during the post-pandemic period were older and more
likely to have chronic obstructive pulmonary disease, chronic kidney disease and cancer than the others. Septic shock, altered mental
status and respiratory failure on arrival at hospital were signiﬁcantly more common during the post-pandemic period. Time from illness
onset to receipt of antiviral therapy was also longer during this period. Early antiviral therapy was less frequently administered to
patients during the post-pandemic period (22.9% versus 10.9%; p 0.009). In addition, length of stay was longer, and need for mechanical
ventilation and intensive-care unit admission were signiﬁcantly higher during the post-pandemic period. In-hospital mortality (5.1% versus
21.2%; p <0.001) was also greater during this period. In conclusion, signiﬁcant epidemiological changes and an increased severity of inﬂu-
enza A (H1N1) 2009 pneumonia were found in the ﬁrst post-pandemic inﬂuenza season. Physicians should consider inﬂuenza A (H1N1)
2009 when selecting microbiological testing and treatment in patients with pneumonia in the upcoming inﬂuenza season.
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Introduction
Pandemic inﬂuenza A (H1N1) virus emerged in Mexico during
the spring of 2009 and spread rapidly worldwide [1], resulting
in the ﬁrst inﬂuenza pandemic of the twenty-ﬁrst century. The
epidemiological features, clinical spectrum of illness and risk
factors for severe disease of pandemic inﬂuenza were broadly
consistent across all countries [2–4]. Cases of infection
occurred mostly in children and young adults. The majority of
patients had self-limited mild-to-moderate uncomplicated dis-
ease. However, some patients developed severe illness and
some died; most of these were adults between the ages of 20
and 50 years, with or without underlying medical conditions
[2–6]. Importantly, most patients requiring intensive-care unit
(ICU) admission had respiratory failure due mainly to primary
inﬂuenza pneumonia [5,7,8]. Bacterial co-infection, although
relatively infrequent, has also been associated with poor prog-
nosis [5,9]. These patterns differed signiﬁcantly from those
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seen during epidemics of seasonal inﬂuenza. In addition, in
experimentally infected animals, the level of pulmonary repli-
cation of the inﬂuenza A (H1N1) 2009 virus was higher than
that of seasonal inﬂuenza viruses [10].
In August 2010, the WHO declared the pandemic (H1N1)
2009 to be over. However, the pandemic inﬂuenza A
(H1N1) 2009 virus is expected to remain in circulation as a
seasonal virus for some years after the pandemic period, and
its behaviour cannot be predicted [11]. The 1918–19 pan-
demic occurred in three waves: a mild ﬁrst wave in spring
and summer 1918, an extremely lethal second wave in
autumn 1918, followed by a less severe third wave in winter
1919 [12,13]. Furthermore, the pattern of successive waves
of varying severity also occurred in the 1957 and 1968 pan-
demics [12]. It is not clear, however, whether past pandem-
ics are an appropriate register for evaluating the current
inﬂuenza pandemic evolution. In addition, no study has spe-
ciﬁcally analysed inﬂuenza A (H1N1) 2009 pneumonia during
the 2010–11 inﬂuenza season [14].
The aim of this study was to ascertain whether there have
been changes in the epidemiology, clinical features and out-
comes of inﬂuenza A (H1N1) 2009 infection. To this end,
we compared hospitalized adults with conﬁrmed inﬂuenza A
(H1N1) 2009 pneumonia during the pandemic period with
those hospitalized during the ﬁrst post-pandemic inﬂuenza
season.
Materials and Methods
Study design and study population
This is a prospective cohort study of adults hospitalized for
at least 24 h with laboratory-conﬁrmed pandemic inﬂuenza
A (H1N1) 2009 virus pneumonia at 14 Spanish teaching hos-
pitals during the pandemic period before the introduction of
the vaccination campaign against the inﬂuenza A (H1N1)
2009 virus (12 June to 10 November 2009) and the ﬁrst
post-pandemic inﬂuenza season (1 December 2010 to 31
March 2011). Conﬁrmed infection was deﬁned as detection
of pandemic inﬂuenza A (H1N1) 2009 virus by real-time RT-
PCR in a respiratory sample (nasopharyngeal aspirate or
nasal plus pharyngeal swab, and samples from the lower
respiratory tract in selected patients). Cases were identiﬁed
at the emergency department by attending physicians or
investigators or by the daily review of the positive microbiol-
ogy results of the RT-PCR. Pandemic inﬂuenza A (H1N1)
2009 virus testing was performed at each institution. The
study was approved by the Institutional Review Board of the
coordinating centre, Hospital Universitari de Bellvitge, and
informed consent was obtained from patients.
For the purpose of this study, patients were divided into
two groups: those hospitalized during the pandemic period
and those hospitalized during the ﬁrst post-pandemic inﬂu-
enza season. Epidemiological and clinical features and out-
comes of hospitalized patients with inﬂuenza A (H1N1) 2009
pneumonia during these periods were compared.
Clinical assessment and follow up
Patients were seen during their hospital stay by one or more
of the investigators at each participating hospital, who
recorded clinical data in a standardized, computer-assisted
protocol. Data were collected on demographic characteris-
tics, comorbidities, body mass index (BMI, the weight in kilo-
grams divided by the square of the height in metres), clinical
signs and symptoms, biochemical analysis, chest X-ray ﬁnd-
ings, antiviral and antibacterial therapy, bacterial co-infection,
time to reach clinical stability [15], complications and in-hos-
pital mortality. For time from onset of symptoms or hospital
arrival until antiviral administration, the day of onset of
symptoms or hospital arrival was considered as day 0,
respectively.
Study variables and deﬁnitions
Pneumonia was deﬁned as the presence of a new inﬁltrate
on a chest radiograph plus fever (temperature ‡38.0C) and/
or respiratory symptoms. Primary viral pneumonia was diag-
nosed in patients presenting pneumonia with negative respi-
ratory and blood bacterial cultures and negative urine
antigen tests. Bacterial co-infection was diagnosed in patients
with one or more positive cultures obtained from blood,
normally sterile ﬂuids, or sputum and/or a positive urinary
antigen test. Sputum Gram staining was performed on a
purulent portion of each sample. Samples were considered
to be of good quality when >25 polymorphonuclear cells and
<10 squamous cells were observed under low-power magni-
ﬁcation. Good-quality specimens were then screened for a
predominant bacterial morphotype by oil immersion micros-
copy.
To stratify patients according to risk, we used community-
acquired pneumonia scores: pneumonia severity index (PSI)
and CURB-65 (confusion, urea nitrogen, respiratory rate,
blood pressure, 65 years of age and older) [16,17].
Underlying medical conditions were assessed according to
the Charlson Comorbidity Index [18]. Other comorbidities
such as immunosuppression, neuromuscular disorders and
sickle-cell disease were also recorded. A vaccinated patient
was any individual who had received a pneumococcal vaccine
in the previous 5 years or a pandemic inﬂuenza A (H1N1)
2009 vaccine in the previous year. Obesity was deﬁned as
BMI ‡ 30. The diagnosis of septic shock was based on the
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deﬁnition of the 1992 ACCP/SCCM Consensus Conference
Committee [19]. Altered mental status was deﬁned as disori-
entation with respect to person, place or time that was not
known to be chronic, stupor or coma. Severe disease was
deﬁned as the composite outcome of ICU admission or
death. The diagnosis of acute respiratory distress syndrome
was established by the attending physicians, based on the
usual practice guidelines [20].
Because hospital admission criteria were not standardized,
we cannot rule out the possibility that factors other than dis-
ease severity may have contributed to site-of-care decisions.
Therefore, to control for possible confounding because of
differences in the criteria governing admission to hospital,
we deﬁned patients as having complicated pneumonia when
any of the following were observed at presentation: intercos-
tal retractions, tachypnoea (respiratory rate ‡30 per min),
PaO2/FiO2 <300 or arterial saturation below 90%), altered
mental status, hypotension (systolic blood pressure
£90 mmHg), pleural effusion, multilobar inﬁltrates in chest
X-rays or bacterial co-infection based on laboratory testing.
Statistical analyses
All proportions were calculated as percentages of the
patients with available data. To detect signiﬁcant differences
between groups, we used the chi-square test or Fisher exact
test for categorical variables and the t test or Mann–Whitney
test for continuous variables, when appropriate. A subgroup
analysis was performed in patients with complicated pneu-
monia at hospital admission to control for factors other than
disease severity that may have contributed to site-of-care
decisions. The results were analysed using SPSS (version
15.0; SPSS Inc., Chicago, IL, USA). A p value of <0.05 was
considered to indicate a signiﬁcant difference. All reported p
values are two-sided.
Results
Three hundred and forty-eight patients with laboratory con-
ﬁrmed inﬂuenza A (H1N1) 2009 pneumonia required hospi-
talization: 234 during the pandemic period (June to
November 2010) and 114 during the ﬁrst post-pandemic
inﬂuenza season period (December 2010 to March 2011).
The epidemiological characteristics of hospitalized patients
during the pandemic and post-pandemic periods are com-
pared in Table 1. Hospitalized patients during the post-pan-
demic inﬂuenza season were older (95% CI of mean
difference 8.1–14.4 years). Regarding age groups, the number
TABLE 1. Epidemiology of inﬂuenza
A (H1N1) 2009 pneumonia by study
periods
All patients
(n = 348)
Pandemic
period (n = 234)
Post-pandemic
season (n = 114) p
Demographic data
Age, median (IQR), years 44 (33–55) 40 (30–50) 53 (43–60) <0.001
Age groups
16–29 years 60 (17.2) 56 (23.9) 4 (3.5) <0.001
30–39 years 78 (22.4) 58 (24.8) 20 (17.5) 0.12
40–49 years 81 (23.3) 57 (24.4) 24 (21.4) 0.49
50–64 years 96 (27.6) 49 (20.9) 47 (41.2) <0.001
‡65 years 33 (9.5) 14 (6) 19 (16.7) 0.001
Male sex 196 (56.3) 129 (55.1) 67 (58.8) 0.52
Pregnancy 12 (3.4) 10 (4.3) 2 (1.8) 0.22
Current smoker 126 (36.4) 89 (38.2) 37 (32.7) 0.32
Alcohol abuse 35 (10.2) 22 (9.5) 13 (11.5) 0.56
Pandemic inﬂuenza vaccine 15 (4.8) 0 (0) 15 (15.3) <0.001
Pneumococcal vaccine, 5 years 16 (5.5) 7 (3.6) 9 (9.4) 0.04
Comorbid conditions
Charlson score, median (IQR) 0 (0–1) 0 (0–1) 1 (0–2) 0.01
Chronic pulmonary disease 80 (23) 53 (22.6) 27 (23.7) 0.83
Asthma 28 (8) 24 (10.3) 4 (3.5) 0.03
COPD 37 (10.6) 17 (7.3) 20 (17.5) 0.004
Chronic heart disease 30 (8.6) 16 (6.8) 14 (12.3) 0.09
Chronic kidney diseasea 21 (6) 9 (3.8) 12 (10.5) 0.01
Chronic liver diseaseb 23 (6.6) 14 (6) 9 (7.9) 0.50
Diabetes mellitus 41 (11.8) 25 (10.7) 16 (14) 0.36
Immunosuppressed 49 (14.1) 29 (12.4) 20 (17.5) 0.19
HIV/AIDS 18 (5.2) 13 (5.6) 5 (4.4) 0.64
Transplant recipients 12 (3.4) 6 (2.6) 6 (5.3) 0.19
Cancer 31 (8.9) 15 (6.4) 16 (14) 0.01
Obesity (BMI ‡ 30)c 55 (29) 33 (30.8) 22 (26.8) 0.54
Data are given as numbers (percentages) except where otherwise indicated. BMI, body mass index; COPD,
chronic obstructive pulmonary disease; HIV/AIDS, human immunodeﬁciency virus/acquired immunodeﬁciency syn-
drome; IQR, interquartile range.
aIncludes patients with mild (creatinine >1.5 mg/dL), and moderate and severe chronic renal disease according to
Charlson Comorbidity Index.
bIncludes patients with mild, moderate and severe chronic liver disease according to Charlson Comorbidity Index.
cData available for 189 patients.
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of patients below the age of 30 years was lower in the post-
pandemic period, but the number of patients above 50 years
was higher. Moreover, hospitalized patients during the post-
pandemic inﬂuenza season had a higher Charlson score and
were more likely to present comorbid conditions, such as
chronic obstructive pulmonary disease, chronic kidney dis-
ease and cancer. Conversely, asthma was more likely to be
present during the pandemic period. No signiﬁcant differ-
ences were found regarding pregnancy, obesity, smoking and
alcohol drinking between groups. Patients hospitalized during
the post-pandemic inﬂuenza season had more frequently
received a previous pandemic inﬂuenza (H1N1) 2009 and
pneumococcal vaccine. Nearly 50% of inﬂuenza-vaccinated
patients were older (>60 years).
Clinical features and laboratory ﬁndings of both groups
are detailed in Table 2. Time from symptoms onset to hospi-
tal admission was signiﬁcantly longer in patients hospitalized
during the post-pandemic inﬂuenza season (95% CI of mean
difference 0.3–1.6 days). Regarding symptoms, signiﬁcant
increases in proportions of patients reporting rhinorrhoea,
chills and dyspnoea during the post-pandemic inﬂuenza sea-
son were noted. As for clinical signs and laboratory ﬁndings,
altered mental status, septic shock, tachypnoea, hyponatra-
emia, respiratory failure and multilobar pneumonia at hospi-
tal presentation were signiﬁcantly more common in patients
hospitalized during the post-pandemic period. The frequency
of bacterial co-infection was similar in the two groups. Strep-
tococcus pneumoniae was the most frequently identiﬁed path-
ogen (26 of 36 cases during the pandemic period and 12 of
16 cases during the post-pandemic period; p 0.83). No signif-
icant difference was found in the frequency of pneumococcal
bacteraemia between the two periods (two and three cases,
respectively; p 0.19).
Patients hospitalized during the post-pandemic inﬂuenza
season period were more frequently classiﬁed into high-risk
classes of the PSI and CURB-65 score. In addition, PSI and
CURB-65 properly identiﬁed more cases of severe disease
during the post-pandemic inﬂuenza season period (29.1%
versus 51.9% and 30.9% versus 42.3%, respectively).
Treatment and clinical outcomes are detailed in Table 3.
Time from illness onset to receipt of antiviral therapy (95%
CI of mean difference 0.4–1.9 days) was longer during the
TABLE 2. Clinical features, labora-
tory ﬁndings, and prognostic scores
of inﬂuenza A (H1N1) 2009 pneu-
monia by study periods
All patients
(n = 348)
Pandemic
period (n = 234)
Post-pandemic
season (n = 114) p
Clinical features
Reported symptoms
Days of symptoms, median (range) 4 (2–7) 4 (2–6) 5 (3–7) 0.007
Cough 317 (91.6) 213 (91.4) 104 (92) 0.84
Shortness of breath 229 (66) 138 (59) 91 (80.5) <0.001
Muscle aches 196 (56.5) 141 (60.3) 55 (48.7) 0.04
Sore throat 76 (22.1) 60 (25.6) 16 (14.5) 0.02
Headache 81 (23.3) 58 (24.8) 23 (20.4) 0.36
Rhinorrhoea 63 (18.3) 34 (14.5) 29 (26.4) 0.008
Diarrhoea 50 (14.4) 32 (13.7) 18 (15.9) 0.57
Vomiting 52 (15) 39 (16.7) 13 (11.5) 0.20
Physical ﬁndings at presentation
Fever (‡38C) 169 (51.1) 123 (55.7) 46 (41.8) 0.01
Septic shock 14 (4) 4 (1.7) 10 (8.8) 0.002
Tachycardia (‡100 beats/min) 148 (46.7) 85 (41.5) 63 (56.3) 0.01
Tachypnoea (‡30 breaths/min) 78 (32.2) 38 (26.2) 40 (41.2) 0.01
Altered mental status 23 (6.6) 10 (4.3) 13 (11.4) 0.01
Wheezing 128 (37.2) 69 (30) 59 (51.8) <0.001
Laboratory ﬁndings
Leukopenia (<4000 per mm3) 73 (21.1) 51 (21.8) 22 (19.6) 0.64
Leukocytosis (‡12 000 per mm3) 65 (18.8) 37 (15.8) 28 (25) 0.04
Lymphopenia (<1500 per mm3) 184 (83) 189 (81.8) 95 (85.6) 0.38
Anaemia (Haematocrit <30%) 23 (6.6) 11 (4.7) 12 (10.5) 0.04
Thrombocytopenia (<100 000 per mm3) 31 (8.9) 13 (5.6) 18 (15.8) 0.002
Elevated ALT (>40 IU/L) 104 (43.7) 68 (42.8) 36 (45.6) 0.68
Elevated AST (>40 IU/L) 114 (44.7) 75 (45.5) 39 (43.3) 0.74
Hyponatraemia 44 (12.7) 21 (9.1) 23 (20.2) 0.004
Respiratory failurea 181 (56.2) 107 (50.7) 74 (66.7) 0.006
Bacterial co-infection 52 (14.9) 36 (15.4) 16 (14) 0.74
Radiographic ﬁndings
Multilobar inﬁltrates 203 (58.5) 125 (53.4) 78 (69) 0.006
Pleural effusion 35 (10.1) 21 (9) 14 (12.4) 0.32
Prognostic scores
High-risk PSI classes (IV-V)b 71 (20.6) 27 (11.7) 44 (38.6) <0.001
High-risk CURB-65 score (‡2) 65 (19) 31 (13.6) 34 (29.8) <0.001
Data are given as numbers (percentages) except where otherwise indicated. ALT, alanine aminotransferase; AST,
aspartate aminotransferase; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure, 65 years of age
and older; PSI, pneumonia severity index.
aPaO2/FiO2 <300 or oxygen saturation <90%.
bPatients were stratiﬁed into the following risk classes according to the PSI score: low risk (£90 points, classes I,
II, and III) and high risk (>90 points, classes IV and V).
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post-pandemic inﬂuenza season period. Also, early antiviral
therapy (£48 h) was less frequently administered to patients
during this period. Time to reach clinical stability and hospital
stay (95% CI of mean difference 0.9–6.2 days) were longer
among hospitalized patients during the post-pandemic period.
ICU admission, acute respiratory distress syndrome, and
need for mechanical ventilation were also higher in these
patients.
Severe disease occurred in 56/234 (23.9%) during the pan-
demic period and in 52/114 (45.6%) during the post-pan-
demic period (p <0.001). Patients with severe disease during
the post-pandemic inﬂuenza season were older (median 42
and 53.5 years, respectively; 95% CI of mean difference 3–
13.6 years). Septic shock was more frequent in hospitalized
patients with severe disease during post-pandemic period. By
contrast, early antiviral therapy was more commonly admin-
istered to hospitalized patients during the pandemic period.
No signiﬁcant differences were found in the other character-
istics.
In-hospital mortality (5.1% versus 21.2%; p <0.001) was
higher in patients during the post-pandemic inﬂuenza season.
Causes of death were respiratory failure/acute respiratory
distress syndrome (three of 13 patients in the pandemic per-
iod and eight of 24 patients in the post-pandemic period),
shock/multiorgan failure (four of 13 patients and nine of 24
patients, respectively), decompensated comorbid condition
(four of 13 patients and two of 24 patients, respectively) and
nosocomial infection (two of 13 patients and ﬁve of 24
patients, respectively).
Table 4 shows epidemiology, clinical features and out-
comes of inﬂuenza A (H1N1) 2009 pneumonia by study peri-
ods according to age. ICU admission and mortality were
higher during the post-pandemic period in younger patients.
In addition, early antiviral therapy was administered less fre-
quently during the post-pandemic period, mainly in younger
patients.
Patients with complicated pneumonia
We performed a subgroup analysis of patients with compli-
cated pneumonia at hospital admission. Of the 234 patients
hospitalized during the pandemic period and the 114 during
the ﬁrst post-pandemic inﬂuenza season period, 140 (59.8%)
TABLE 4. Epidemiology, clinical features and outcomes of inﬂuenza A (H1N1) 2009 pneumonia by study periods according to
age
Pandemic period Post-pandemic period
16–29 years 30–49 years 50–64 years >64 years 16–29 years 30–49 years 50–64 years >64 years
Male sex 27 (48.2) 66 (57.4) 30 (61.2) 6 (42.9) 1 (25) 24 (54.5) 32 (68.1) 10 (52.6)
Comorbidities 17 (30.4) 52 (45.2) 37 (75.5) 12 (85.7) 1 (25) 17 (38.6) 32 (68.1) 18 (94.7)
Septic shock 1 (1.8) 1 (0.9)a 2 (4.1) 0 (0) 1 (25) 4 (9.1)a 3 (6.4) 2 (10.5)
Altered mental status 2 (3.6) 4 (3.5) 3 (6.1) 1 (7.1) 1 (25) 2 (4.5) 7 (14.9) 3 (15.8)
Bacterial co-infection 9 (16.1) 20 (17.4) 6 (12.2) 1 (7.1) 0 (0) 5 (11.4) 8 (17) 3 (15.8)
Early antiviral therapy (£48 h) 14 (25.5) 23 (21.3)a 9 (21.4) 4 (30.8) 0 (0) 1 (2.3)a 9 (20) 2 (10.5)
ICU admission 11 (19.6) 25 (21.7)a 11 (22.4)a 6 (42.9) 1 (25) 20 (45.5)a 22 (46.8)a 5 (26.3)
Mortality 3 (5.4)a 5 (4.3)a 2 (4.1)a 2 (14.3) 2 (50)a 8 (18.6)a 11 (23.4)a 4 (21.1)
Data are given as numbers (percentages) except where otherwise indicated.
ICU, intensive care unit.
ap value <0.05.
TABLE 3. Treatment and clinical
outcomes of inﬂuenza A (H1N1)
2009 pneumonia by study periods
All patients
(n = 348)
Pandemic
period (n = 234)
Post-pandemic
season (n = 114) p
Treatment
Antiviral treatment 341 (98) 229 (97.9) 112 (98.2) 0.81
Time from symptoms onset to antiviral therapy,
median (IQR), days
5 (3–7) 5 (3–7) 5.5 (4–7) 0.002
Early therapy (£48 h after symptoms onset) 62 (18.9) 50 (22.9) 12 (10.9) 0.009
Initiation of therapy the day of hospital arrival 106 (31.5) 61 (27.1) 45 (40.5) 0.01
Antibacterial treatment 341 (98) 228 (97.4) 113 (99.1) 0.29
Clinical outcomes
Length of hospital stay, median (IQR), days 7 (5–12) 7 (5–11) 9 (6–16) 0.005
In-hospital complications
Nosocomial infections 27 (7.8) 14 (6) 13 (11.4) 0.07
Acute cardiac complicationsa 22 (6.3) 10 (4.3) 12 (10.5) 0.02
ICU admission 101 (29) 53 (22.6) 48 (42.1) <0.001
Mechanical ventilation 65 (18.7) 30 (12.8) 35 (30.7) <0.001
ARDS 51 (14.7) 21 (9) 30 (26.3) <0.001
In-hospital mortality 36 (10.3) 12 (5.1) 24 (21.2) <0.001
Data are given as numbers (percentages) except where otherwise indicated.
ARDS, acute respiratory distress syndrome; ICU, intensive-care unit, IQR, interquartile range.
aIncludes acute coronary syndromes, new onset arrhythmias and decompensated heart failure.
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and 91 (79.8%), respectively, had at least one criterion of
complicated pneumonia. The differences regarding epidemiol-
ogy, clinical characteristics and severity found in the sub-
group of patients with complicated pneumonia at hospital
admission were similar to those encountered in the entire
population (data not shown).
Discussion
This prospective study shows that there were signiﬁcant
changes in the epidemiology and an increased severity of
inﬂuenza A (H1N1) 2009 pneumonia during the ﬁrst post-
pandemic inﬂuenza season. Hospitalized adults with inﬂuenza
A (H1N1) 2009 pneumonia during the recent ﬁrst post-pan-
demic inﬂuenza season were older and were more likely to
have comorbid conditions than those in the pandemic per-
iod. They also had a longer time to antiviral administration
and had more severe disease at hospital presentation, as evi-
denced by the higher percentages of septic shock, altered
mental status, respiratory failure and values of PSI and
CURB-65 scores. Admission to ICU and need for mechanical
ventilation were also more frequent. Importantly, in-hospital
mortality was four-fold higher in the post-pandemic period
than during the pandemic.
Although pregnancy, obesity and bacterial co-infection
have been associated with poor prognosis during the pan-
demic (H1N1) 2009 [5,21–23], we did not ﬁnd signiﬁcant dif-
ferences in the prevalence of these factors between the two
study periods. Moreover, we performed a subgroup analysis
of patients with complicated pneumonia to control for rea-
sons other than disease severity that might have contributed
to site-of-care decisions. Differences found between periods
in this subgroup of patients with severe pneumonia were
similar to those encountered in the entire population. On
the other hand, it has recently been reported that the pan-
demic inﬂuenza A (H1N1) 2009 virus has remained geneti-
cally stable, with no increase in virulence since its origin
[24,25]. Consequently, other factors may have been involved
in the striking changes documented in the present study.
A recent study [12] has shown that immune protection
naturally acquired during the ﬁrst wave of the 1918 inﬂuenza
pandemic provided mortality and morbidity protection dur-
ing the successive pandemic wave. Several investigations have
evaluated the frequency of the pre-existing cross-reactive
antibodies and the acquisition of immunity in the pre-pan-
demic and post-pandemic (H1N1) 2009 periods [26–29].
These studies have found higher seropositivity in older
patients (those born before 1957) and negligible or minimal
seropositivity in younger patients in the pre-pandemic per-
iod. By contrast, after the pandemic period, higher seroposi-
tivity against pandemic (H1N1) virus was found among the
school-aged population and young adult patients (<30 years
old). Seropositivity rates were similar to those in the pre-
pandemic period in the elderly population, indicating low
infection rates. These data show that patients aged >30 years
developed lower immune protection capable of neutralizing
pandemic inﬂuenza A (H1N1) 2009 virus. Our ﬁndings of an
older age in hospitalized patients during the post-pandemic
inﬂuenza season are therefore consistent with the seropreva-
lence studies mentioned above.
Moreover, other studies have reported that the imple-
mentation of vaccination against the inﬂuenza A (H1N1)
2009 virus has been suboptimal [30–32]. In the present
study, although 61% of the hospitalized patients with pneu-
monia during the post-pandemic period had one or more
criteria for inﬂuenza A (H1N1) 2009 vaccination according
to current guideline recommendations, only 17% of them
had been vaccinated. These data reinforce the importance of
vaccination in vulnerable subjects after the pandemic period.
However, it should be noted that some studies have
reported a vaccine effectiveness of 60–93% [33].
The WHO strongly recommends administration of antivi-
ral treatment as soon as possible to all hospitalized patients
during the post-pandemic inﬂuenza season [34]. In the pres-
ent study, however, time from illness onset to receipt of
antiviral therapy was signiﬁcantly longer in patients hospital-
ized in the post-pandemic period than during the pandemic.
Importantly, a large proportion of patients did not receive
antiviral therapy on the day of arrival at the hospital, in
spite of previous results from observational studies of hos-
pitalized patients with pandemic (H1N1) 2009 showing that
early antiviral treatment was associated with a decrease in
viral load, disease severity and mortality [35–39]. Therefore,
it can be hypothesized that the delay in the administration
of antiviral treatment during the ﬁrst post-pandemic inﬂu-
enza season may explain at least in part the differences in
severity and outcomes found between the study periods. It
is important that physicians should be aware that patients
presenting with pneumonia in the emergency department
during the upcoming inﬂuenza seasons may have inﬂuenza A
(H1N1) 2009 and may require a targeted diagnostic and
therapeutic approach.
Moreover, the baseline differences of greater age and the
higher number of co-morbid illnesses between the two study
periods may be also a possible explanation for the higher
morbidity and mortality documented during the post-pan-
demic inﬂuenza season. In this respect, studies involving
patients with pandemic (H1N1) 2009 found that older
patients had the highest case fatality rate. Additionally, sev-
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eral comorbidities have been associated with complications,
ICU admission and mortality during pandemics [2–6].
Strengths of the present study are its prospective and
multicentre design, the large number of consecutive hospital-
ized patients with pneumonia included in both periods, and
the comprehensive clinical data collection. In addition, this
study was conducted in geographically diverse settings across
Spain, a feature that improves the external validity of the
results. However, our study has several limitations that
should be acknowledged. We only examined hospitalized
patients with inﬂuenza A (H1N1) 2009 pneumonia and can-
not make assertions about other populations. Hospital crite-
ria decisions were not standardized and we did not have
information regarding the percentage of patients tested by
PCR for H1N1 inﬂuenza virus in each study period. More-
over, we have no data regarding the percentage of patients
with inﬂuenza A (H1N1) 2009 pneumonia treated by pri-
mary-care physicians. Likewise, we could not calculate inci-
dence rates and the differences between study periods.
However, according to data provided by the Spanish Inﬂu-
enza Surveillance System (http://vgripe.isciii.es/gripe/inicio.do),
the highest incidence of inﬂuenza cases during the pandemic
period (2009) were in weeks 43–47 (372 cases/100 000
inhabitants) and during post-pandemic inﬂuenza season per-
iod (2011) were in weeks 2–3 (230 cases/100 000 inhabit-
ants). Finally, serum samples to determine antibodies against
inﬂuenza A (H1N1) 2009 virus were not obtained and we
did not perform testing to identify emerging new antigenic
virus.
In conclusion, signiﬁcant epidemiological changes and an
increased severity of inﬂuenza A (H1N1) 2009 pneumonia
were found in the ﬁrst post-pandemic inﬂuenza season. Phy-
sicians dealing with patients with pneumonia in the upcoming
inﬂuenza seasons should carefully consider inﬂuenza A
(H1N1) 2009 as a possible causative agent when ordering
microbiological tests and selecting treatment. Early diagnosis
and antiviral therapy of inﬂuenza A (H1N1) 2009 pneumonia
would help to improve patient outcomes.
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